Theriva Biologics: No Material Development to Account for Stock Activity

Dow Jones

2025/10/25

By Josh Beckerman

Theriva Biologics, whose shares rose sharply Friday, said there has been no reason to account for the unusual market action.

The company added that there wasn't any material development in its business and affairs not previously disclosed.

Theriva's response to the unusual market action was pursuant to Section 401(d) of the NYSE Company Guide, it said.

The stock was recently up 44%, to 49 cents, on volume of more than 479 million shares, compared with a 65-day average of 4.9 million shares.

On Monday, expanded metastatic pancreatic ductal adenocarcinoma data from Theriva's VIRAGE Phase 2b trial was presented at the European Society for Medical Oncology Annual Congress.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 24, 2025 15:01 ET (19:01 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2578428995"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578428995\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578428995?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-25 03:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578428995","market":"nz","top_or_hot":-1,"title":"Theriva Biologics: No Material Development to Account for Stock Activity","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TOVX\">Theriva Biologics</a>, whose shares rose sharply Friday, said there has been no reason to account for the unusual market action. \n</p>\n<p>\n  The company added that there wasn't any material development in its business and affairs not previously disclosed. \n</p>\n<p>\n  Theriva's response to the unusual market action was pursuant to Section 401(d) of the NYSE Company Guide, it said. \n</p>\n<p>\n  The stock was recently up 44%, to 49 cents, on volume of more than 479 million shares, compared with a 65-day average of 4.9 million shares. \n</p>\n<p>\n  On Monday, expanded metastatic pancreatic ductal adenocarcinoma data from Theriva's VIRAGE Phase 2b trial was presented at the European Society for Medical Oncology Annual Congress. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 24, 2025 15:01 ET (19:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Theriva Biologics: No Material Development to Account for Stock Activity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTheriva Biologics: No Material Development to Account for Stock Activity\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-25 03:01</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TOVX\">Theriva Biologics</a>, whose shares rose sharply Friday, said there has been no reason to account for the unusual market action. \n</p>\n<p>\n  The company added that there wasn't any material development in its business and affairs not previously disclosed. \n</p>\n<p>\n  Theriva's response to the unusual market action was pursuant to Section 401(d) of the NYSE Company Guide, it said. \n</p>\n<p>\n  The stock was recently up 44%, to 49 cents, on volume of more than 479 million shares, compared with a 65-day average of 4.9 million shares. \n</p>\n<p>\n  On Monday, expanded metastatic pancreatic ductal adenocarcinoma data from Theriva's VIRAGE Phase 2b trial was presented at the European Society for Medical Oncology Annual Congress. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 24, 2025 15:01 ET (19:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TOVX","symbol_name":"Theriva Biologics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578428995","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578428995","pubTimestamp":1761332460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Theriva Biologics, whose shares rose sharply Friday, said there has been no reason to account for the unusual market action.The company added that there wasn't any material development in its business and affairs not previously disclosed.Theriva's response to the unusual market action was pursuant to Section 401 of the NYSE Company Guide, it said.The stock was recently up 44%, to 49 cents, on volume of more than 479 million shares, compared with a 65-day average of 4.9 million shares.On Monday, expanded metastatic pancreatic ductal adenocarcinoma data from Theriva's VIRAGE Phase 2b trial was presented at the European Society for Medical Oncology Annual Congress.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TOVX":"Theriva Biologics","BK4139":"生物科技"},"translate_title":"Theriva Biologics：没有重大开发来解释库存活动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TOVX":1.5},"content_text":"By Josh Beckerman \n\n\n \n\n\nTheriva Biologics, whose shares rose sharply Friday, said there has been no reason to account for the unusual market action. \n\n\n  The company added that there wasn't any material development in its business and affairs not previously disclosed. \n\n\n  Theriva's response to the unusual market action was pursuant to Section 401(d) of the NYSE Company Guide, it said. \n\n\n  The stock was recently up 44%, to 49 cents, on volume of more than 479 million shares, compared with a 65-day average of 4.9 million shares. \n\n\n  On Monday, expanded metastatic pancreatic ductal adenocarcinoma data from Theriva's VIRAGE Phase 2b trial was presented at the European Society for Medical Oncology Annual Congress. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 24, 2025 15:01 ET (19:01 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}